{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:22:51Z","timestamp":1785435771338,"version":"3.56.0"},"reference-count":28,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Basilea Pharmaceutica International Ltd., Allschwil, Switzerland"},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"crossref","award":["HHSO100201600002C"],"award-info":[{"award-number":["HHSO100201600002C"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"crossref"}]},{"award":["HHSO100201600002C"],"award-info":[{"award-number":["HHSO100201600002C"]}],"id":[{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Ceftobiprole is an advanced-generation cephalosporin approved in Europe in 2013 for various indications, and in the United States (US) in 2024 for community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia, including right-sided endocarditis. Methods: The in vitro activity of ceftobiprole and comparators was evaluated against 2793 Streptococcus pneumoniae causing lower respiratory tract infections in 32 US sites (2016\u20132020), including against subsets from various geographic regions, resistance phenotypes and prevalent serotypes. Results: Ceftobiprole inhibited 99.5% of all S. pneumoniae at the MIC of \u22640.5 mg\/L (MIC50\/90, 0.015\/0.25 mg\/L). Susceptibilities of 98.2% to 100% were observed for ceftobiprole against isolates originating from each surveyed year or each US Census Division. Ceftobiprole retained activity against isolates resistant to macrolides (98.8%), tetracycline (98.2%), oral penicillin (95.4%), against multidrug-resistant isolates (97.0%), and various serotypes (93.8\u2013100%). Ceftriaxone (97.4%) and amoxicillin\u2013clavulanate (95.1%) also showed elevated susceptibilities overall, but inconsistent results and lower than those observed for ceftobiprole were noted against isolates with elevated penicillin MIC or specific serotypes (i.e., 19A). Conclusions: These in vitro results, coupled with documented clinical efficacy, indicate that ceftobiprole is a valuable option to treat CABP caused by S. pneumoniae in the US.<\/jats:p>","DOI":"10.3390\/antibiotics15040375","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:09:00Z","timestamp":1775549340000},"page":"375","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Vitro Antimicrobial Activity of Ceftobiprole and Comparator Agents Against Streptococcus pneumoniae Responsible for Lower Respiratory Tract Infections in the United States (2016\u20132020), Including Resistant Subsets and Select Serotypes"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-6644","authenticated-orcid":false,"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, IA 52317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, IA 52317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Jones","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., 4123 Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, IA 52317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Li, J., Cheng, G., Qin, X., and Liu, J. (2025). Streptococcus pneumoniae beta-lactam resistance: Epidemiological trends, molecular drivers, and innovative control strategies in the post-pandemic era. Clin. Microbiol. Rev., 38.","DOI":"10.1128\/cmr.00082-25"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.idc.2019.08.007","article-title":"Invasive pneumococcal and meningococcal disease","volume":"33","author":"Fitzgerald","year":"2019","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3121\/cmr.2022.1767","article-title":"Changes in Streptococcus pneumoniae susceptibility in Wisconsin: Implications for clinical treatment decisions for respiratory infections","volume":"20","author":"Munson","year":"2022","journal-title":"Clin. Med. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"iv39","DOI":"10.1093\/jac\/dkz286","article-title":"Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007\u201316","volume":"74","author":"Golden","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Higgs, C., Kumar, L.S., Stevens, K., Strachan, J., Korman, T., Horan, K., Daniel, D., Russell, M., McDevitt, C.A., and Sherry, N.L. (2023). Comparison of contemporary invasive and non-invasive Streptococcus pneumoniae isolates reveals new insights into circulating anti-microbial resistance determinants. Antimicrob. Agents Chemother., 67.","DOI":"10.1128\/aac.00785-23"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2666-5247(21)00064-1","article-title":"Antimicrobial resistance in paediatric Streptococcus pneumoniae isolates amid global implementation of pneumococcal conjugate vaccines: A systematic review and meta-regression analysis","volume":"2","author":"Andrejko","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bensaci, M.F., Bauer, K.A., Klinker, K., Cota, J., Mendes, R.E., and Feemster, K. (2026). Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022\u20132023). J. Antimicrob. Chemother., 81.","DOI":"10.1093\/jac\/dkaf414"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Corcione, S., De Benedetto, I., Carlin, M., Pivetta, E.E., Scabini, S., Grosso, C., Shbaklo, N., Porta, M., Lupia, E., and De Rosa, F.G. (2024). Real-world experience of ceftobiprole for community- and hospital-acquired pneumonia from a stewardship perspective. Microorganisms, 12.","DOI":"10.3390\/microorganisms12040725"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/10600280241293773","article-title":"Ceftobiprole Medocaril: A New Fifth-Generation Cephalosporin","volume":"59","author":"Zimmerman","year":"2025","journal-title":"Ann. Pharmacother."},{"key":"ref_13","unstructured":"US Food and Drug Administration (2025, January 16). Susceptibility Test Interpretive Criteria (STIC), Available online: https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2008.02.008","article-title":"Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2005\u20132006)","volume":"61","author":"Fritsche","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pfaller, M.A., Flamm, R.K., Mendes, R.E., Streit, J.M., Smart, J.I., Hamed, K.A., Duncan, L.R., and Sader, H.S. (2019). Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01566-18"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sader, H.S., Smart, J.I., Mendes, R.E., and Castanheira, M. (2025). Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022. Antimicrob. Agents Chemother., 69.","DOI":"10.1128\/aac.01402-24"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1128\/AAC.00238-06","article-title":"Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x","volume":"50","author":"Davies","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ijantimicag.2012.02.016","article-title":"Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone","volume":"39","author":"Davies","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1128\/AAC.00590-10","article-title":"Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin","volume":"54","author":"Davies","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mohanty, S., Johnson, K.D., Yu, K.C., Watts, J.A., and Gupta, V. (2022). A multicenter evaluation of trends in antimicrobial resistance among Streptococcus pneumoniae isolates from adults in the United States. Open Forum Infect. Dis., 9.","DOI":"10.1093\/ofid\/ofac420"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"116838","DOI":"10.1016\/j.diagmicrobio.2025.116838","article-title":"In Vitro activity of ceftobiprole against 20,255 recent clinical bacterial isolates in Canada (CANWARD 2015\u20132023)","volume":"112","author":"Gemme","year":"2025","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Canton, R., Hamed, K., Wiktorowicz, T., Redder, N., Jemmely, N., Quevedo, J., and Henriksen, A.S. (2022). In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016\u201319). JAC Antimicrob. Resist., 4.","DOI":"10.1093\/jacamr\/dlac030"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jgar.2022.05.001","article-title":"Susceptibility of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2019 from different European territories","volume":"29","author":"Hawser","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ganaie, F.A., Beall, B.W., Yu, J., van der Linden, M., McGee, L., Satzke, C., Manna, S., Lo, S.W., Bentley, S.D., and Ravenscroft, N. (2025). Update on the evolving landscape of pneumococcal capsule types: New discoveries and way forward. Clin. Microbiol. Rev., 38.","DOI":"10.1128\/cmr.00175-24"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jinf.2020.07.035","article-title":"Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009\u20132017","volume":"81","author":"Suaya","year":"2020","journal-title":"J. Infect."},{"key":"ref_26","unstructured":"Clinical and Laboratory Standards Institute (2024). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Clinical and Laboratory Standards Institute. CLSI Standard M07 12th Edition 2024."},{"key":"ref_27","unstructured":"Clinical and Laboratory Standards Institute (2025). Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute. CLSI Standard M100 35th Edition 2025."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/jac\/dkv107","article-title":"Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007\u201313","volume":"70","author":"Golden","year":"2015","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/4\/375\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:23:11Z","timestamp":1775708591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/4\/375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["antibiotics15040375"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15040375","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}